Search This Blog

Monday, April 20, 2026

Lavrov, Araghchi discuss US-Iran ceasefire in a call

 Russian Foreign Minister Sergey Lavrov held a phone conversation with his Iranian counterpart Abbas Araghchi (pictured left) on Monday, during which the two diplomats discussed the conflict in the Middle East and the ceasefire between the United States and Iran.

According to the Russian Foreign Ministry's statement, Araghchi told his Russian counterpart about the "ceasefire violations" that Tehran claims the US committed, including the "illegal" naval blockade of the Strait of Hormuz and the seizure of an Iranian ship. He also confirmed Iran's willingness to do "everything in its power" to facilitate "unimpeded" passage of Russian ships through the critical Middle Eastern waterway.

On the other hand, the Russian foreign minister emphasized the need for the ceasefire to be maintaining and the importance of preventing "relapse into armed confrontation" by continuing diplomatic efforts.

https://breakingthenews.net/Article/Lavrov-Araghchi-discuss-US-Iran-ceasefire-in-a-call/66106763

Iran says no decision yet on talks as Pakistan prepares to host US team

 Iran said on Monday it had not yet decided whether to join a second round of talks with the United States, even as Pakistan prepared to host a US delegation, with Tehran accusing Washington of violating the ceasefire and showing no real seriousness about diplomacy.

Foreign Ministry spokesperson Esmaeil Baghaei said Iran had no plan as of now for the next round of negotiations and said US actions had only deepened mistrust.

“As I am speaking to you now, we have no plan for the next round of negotiations,” he said.

Baghaei said Washington had undermined the process from the outset of the ceasefire.

He said the United States first tried to argue that Lebanon was not part of the truce, despite Pakistan’s mediator saying otherwise, and then continued what Iran describes as a naval blockade and other hostile actions in and around the Strait of Hormuz, including an attack on an Iranian commercial vessel.

He said such actions were clear ceasefire violations and that the blockade itself amounted to aggression under international law.

“Behavior and words are completely incompatible,” he said, adding that Iran would decide its next steps based only on national interests, not deadlines or ultimatums.

Baghaei said Iran had not started the war and had acted only in self-defense. He warned that if the United States or Israel launched any new attack, Iran’s armed forces would respond.

He also said Tehran could not forget what he called two US betrayals of diplomacy over the past year, saying Washington had twice attacked Iran during diplomatic processes.

“We cannot forget that twice America betrayed diplomacy,” he said.

Pakistan remains sole mediator

Baghaei said Pakistan remained Iran’s only formal mediator, though other countries were making efforts.

He said Iran was still reviewing the latest package conveyed through Pakistan after a US 15-point proposal, Iran’s 10-point response, discussions in Islamabad and further review during Pakistani army chief Asim Munir’s visit to Tehran.

He rejected suggestions that Iran had made a wholly new proposal, saying Tehran’s position had remained steady while the US side kept changing its demands.

“The American side keeps changing its demands, but we have remained steadfast,” he said.

He said some US demands were unacceptable and that repeated insistence on them would not change Iran’s position.

Baghaei also dismissed trust as a basis for negotiations with Washington.

“There is no trust,” he said.

Hormuz, Europe and red lines

Much of Baghaei’s remarks focused on the Strait of Hormuz. He said Iran’s actions there were lawful and defensive, arguing that before the US and Israeli attacks there had been no problem in the waterway.

“Before February 28, the Strait of Hormuz was safe and secure,” he said.

He said the international community should hold the United States and Israel responsible for the current insecurity, not Iran.

He added that Iranian authorities were still examining whether recent incidents involving Indian-linked ships had in fact been caused by Iranian forces.

Baghaei said as long as the current situation continued, it was unrealistic to speak of a full return to normal traffic through Hormuz. He said Iran had concluded that new rules or protocols would be needed to ensure safe passage in the future.

He also rejected European criticism, including comments from EU foreign policy chief Kaja Kallas, saying Europe could not invoke international law selectively.

“You cannot use international law as a convenient tool,” he said.

Baghaei said Iran would not negotiate over its defense capabilities and said the transfer of enriched uranium had never been an Iranian option in the talks.

On oil, he said Iran was using all available means to keep its oil industry functioning and maintain exports despite the blockade and wartime pressure.

https://www.iranintl.com/en/202604191069

CENTCOM says 27 vessels redirected since start of iranian port blockade

 

Central Command says since the commencement of the blockade against ships entering or exiting Iranian ports and coastal areas, US forces have directed 27 vessels to turn around or return to an Iranian port.


https://www.iranintl.com/en/liveblog/202604194357

Seized Iranian ship Touska likely carrying military dual-use items - Reuters

 

The Iranian-flagged container ship Touska, which was boarded and seized by US forces on Sunday, is likely to have what Washington deems dual-use items that could be used by the military onboard, Reuters reported citing maritime security sources.

The small container ship is part of the Islamic Republic of Iran Shipping Lines (IRISL) group, which has been hit with US sanctions. It was boarded on Sunday off the coast of Iran's Chabahar port in the Gulf of Oman and last reported its position at 13:08 GMT, the report added citing ship-tracking data on the Marine Traffic platform.

The security sources cited by Reuters said their initial assessments were that the vessel was likely carrying dual-use items after a voyage from Asia.

https://www.iranintl.com/en/liveblog/202604194357

Iran to grant selective internet access to businesses via ‘internet pro’

 

Iran's Supreme National Security Council (SNSC) has approved a plan to provide global internet access to specific business sectors to maintain economic activity, a senior lawmaker said on Monday.

Reza Alizadeh, chairman of the Iranian Parliament's Industries and Mines Committee, provided details of a resolution that introduces a specialized access system referred to as "Internet Pro."

He said the effort aims to ensure that the industrial, production, trade, and export sectors can carry out their work with ease under current conditions.

Alizadeh said the rollout is being conducted in stages. In the first phase, access was provided to commercial card holders through the Chamber of Commerce. The second phase provided international internet access to organizations and agencies related to production, industry, and trade, while observing security considerations.

Authentication for smaller production units is currently underway to grant them access to "Internet Pro" gradually, Alizadeh said. He added that any decision regarding the scope or restriction of global internet access remains with security agencies and the Supreme National Security Council.

https://www.iranintl.com/en/liveblog/202604194357

Russia, Iran foreign ministers hold phone call

 

Russian Foreign Minister Sergey Lavrov spoke by phone with his Iranian counterpart Abbas Araghchi, Russia’s foreign ministry said on Monday.

Aluminum Giant Alcoa To Sell Dormant Smelter To Bitcoin-Miner NYDIG: Report

  by Amin Haqshanas via CoinTelegraph.com,

US aluminium giant Alcoa is reportedly nearing a deal to offload its long-idle Massena East smelter in upstate New York to Bitcoin mining firm New York Digital Investment Group (NYDIG).

The company is in advanced discussions and expects the transaction to close “in the middle part of this year,” CEO Bill Oplinger told Bloomberg on Friday. The site, located along the St. Lawrence River, has been inactive since 2014 after Alcoa shut it down amid rising energy costs and global competition.

Built for 24/7 heavy industrial operations, aluminum smelters come with pre-existing substations, transmission lines and high-capacity grid connections. That makes them attractive targets for Bitcoin miners and data center operators, who often spend years securing similar infrastructure approvals from scratch.

Massena East also benefits from hydropower supplied by the New York Power Authority, a key draw for energy-intensive computing firms seeking low-cost and lower-carbon power sources.

US smelters reborn as crypto, AI data centers

The potential sale comes amid a broader trend across the US, where retired industrial sites are being repurposed for digital infrastructure. Earlier this year, Century Aluminum sold its Hawesville smelter in Kentucky to TeraWulf for $200 million, with plans to convert it into a high-performance computing and AI facility rather than traditional industrial use.

TeraWulf shares are up 80% YTD. Source Bloomberg 

Meanwhile, NYDIG has been growing its footprint in Bitcoin mining infrastructure. The firm, owned by Stone Ridge, already holds a stake in Coinmint, which operates mining hardware at the same campus under a long-term lease.

Last year, Crusoe Energy also agreed to sell its Bitcoin mining business, including its digital flare mitigation operations, to NYDIG.

Bitcoin miners pivot to AI

NYDIG’s renewed push into Bitcoin mining comes as other miners are increasingly pivoting toward AI and cloud computing as shrinking margins in mining push them to diversify revenue streams.

Earleir this year, MARA Holdings acquired a 64% stake in French infrastructure company Exaion, giving the company a foothold in AI services. Other miners, including Hive, Hut 8, TeraWulf and Iren, are also repurposing mining facilities into data centers, while some, such as CoreWeave, have fully transitioned into AI-focused infrastructure.

https://www.zerohedge.com/crypto/aluminum-giant-alcoa-sell-dormant-smelter-bitcoin-miner-nydig-report

DoJ Opens Criminal Probe Into Meatpacking Cartel As Food Stocks Slide

 Shares of Tyson Foods and Smithfield Foods fell in late-morning trading in New York after The Wall Street Journal reported that the Justice Department's antitrust division has opened a criminal probe into major meatpackers.

The report follows President Trump's push for an investigation into meatpackers as supermarket beef prices remain near record highs.

Criminal antitrust cases are typically brought for alleged price-fixing, collusion, or bid-rigging. While the DoJ previously disclosed an investigation into beef companies after Trump called for action, it had not provided details on whether it was criminal.

In early November, Trump publicly stated, "I have asked the DOJ to immediately begin an investigation into the Meat Packing Companies who are driving up the price of Beef through illicit collusion, price fixing, and price manipulation."

"We will always protect our American ranchers, and they are being blamed for what is being done by majority foreign-owned meat packers, who artificially inflate prices and jeopardize the security of our nation's food supply," Trump continued.

Beef prices at supermarkets have soared to record highs after years of drought, and elevated input prices led to the smallest U.S. herd in a generation. Trump's tariffs on Brazil, a major beef exporter, have also curbed imports.

Also, last year, Trump suggested the U.S. would buy Argentine beef to increase domestic supplies and curb higher prices for Americans. This, in turn, angered U.S. cattle ranchers.

Shares of top publicly traded meatpackers, including Tyson Foods and Smithfield Foods, fell after the WSJ report hit.

Tyson Foods

Smithfield Foods

Rep. Thomas Massie (R-Ky.) has pointed out that "Four meat packers control 85 percent of the meat processed in the U.S."

Meanwhile, Senate Democratic Leader Chuck Schumer (D-N.Y.) and 12 other senators have proposed legislation that would force the nation's largest meatpackers to break up their operations across beef, pork, and poultry.

Related:

The DOJ's criminal investigation into beef companies comes as the Trump administration attempts to push forward with affordability policies as the K-shaped economy continues hammering the working poor.

https://www.zerohedge.com/markets/doj-opens-criminal-probe-meatpacking-cartel-food-stocks-slide

SEC, CFTC Propose Narrowing Hedge Fund Reporting Requirements

 


Wall Street’s top regulators unveiled a plan to reduce hedge fund reporting requirements, according to a statement.

The Commodity Futures Trading Commission and Securities and Exchange Commission jointly proposed eliminating filing requirements for smaller advisers and raising the threshold for all filers from $150 million in private fund assets under management to $1 billion. The agencies use the data collected confidentially under so-called Form PF for examinations and investigations tied to private fund advisers.

https://www.bloomberg.com/news/articles/2026-04-20/sec-cftc-propose-narrowing-hedge-fund-reporting-requirements

Priority Review to sBLA for PADCEV™ + Keytruda for Muscle-Invasive Bladder Cancer

 

  • Submission based on statistically significant event-free and overall survival data from the Phase 3 EV-304 trial
  • Building on the existing indication in cisplatin-ineligible muscle-invasive bladder cancer (MIBC), if approved, this regimen would be the first and only perioperative treatment for patients with MIBC regardless of cisplatin eligibility, marking a potential new standard of care

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental Biologics License Application (sBLA) for perioperative (before and after surgery) PADCEV™ (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate, in combination with the PD-1 inhibitor Keytruda® (pembrolizumab) or Keytruda QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) as treatment for patients with muscle-invasive bladder cancer (MIBC). This regimen was FDA-approved in November 2025 for use as perioperative treatment in cisplatin-ineligible patients with MIBC. This filing seeks to expand the indication to patients with MIBC regardless of cisplatin eligibility. The FDA grants Priority Review to medicines that may offer significant advances in treatment or may provide a treatment where limited therapy options exist.i Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date of August 17, 2026.

https://www.pfizer.com/news/press-release/press-release-detail/us-fda-grants-priority-review-sbla-padcevtm-keytrudar

Apollo (APO) Acquires Minority Stake in McKesson's Medical-Surgical Solutions Business

 On April 20, 2026, McKesson Corporation is finalizing a significant deal with Apollo's managed funds, wherein Apollo will obtain a minority share in McKesson's Medical-Surgical Solutions (MMS) division. This agreement marks a crucial step in McKesson's broader strategy to separate MMS in anticipation of a future public offering.

https://www.gurufocus.com/news/8803122/apollo-apo-acquires-minority-stake-in-mckessons-medicalsurgical-solutions-business

AstraZeneca’s tozorakimab meets primary endpoint in pivotal Phase III MIRANDA COPD trial

 



Tozorakimab delivered a statistically significant, clinically meaningful reduction in moderate-to-severe COPD exacerbations in the MIRANDA trial

Phase III MIRANDA results support planned regulatory submissions for tozorakimab as a potential first-in-class biologic therapy

https://finviz.com/quote.ashx?t=AZN&p=d
Hello! Chat with our bot to learn more about i

Arcus Biosciences Discontinues Lung Cancer Trial With Gilead

 Arcus Biosciences is discontinuing a phase 3 lung cancer trial it was conducting with Gilead Sciences.

Arcus, an oncology company, said Monday it was ending the trial due to futility, meaning it doesn't expect the trial to yield positive results. It also ended a phase 2 study.

Gilead's option rights to certain early pipeline programs under its 2020 agreement with Arcus will end in July due to Gilead's decision to not make the option continuation payment to Arcus.

Gilead won't have option rights to additional Arcus programs, but will maintain its existing time-limited options.

The decision is based on the recommendation of the Independent Data Monitoring Committee, following its review of data from a pre-planned futility analysis.

The analysis didn't assess safety, but no new safety issues were identified during regular reviews.

Gilead is communicating with investigators to determine appropriate next steps for patients in the studies.

https://www.morningstar.com/news/dow-jones/202604204056/arcus-biosciences-discontinues-lung-cancer-trial-with-gilead

Merck’s early PD-1/VEGF data competitive in lung cancer, but Summit ‘Looms Large’

 

While Merck’s PD-1/VEGF asset appears to match the performance of Summit Therapeutics’ ivonescimab, the pharma’s Phase 1/2 readout in non-small cell lung cancer still leaves analysts with some questions moving into later-stage development.

Merck and Sino Biopharmaceutical’s anti-PD-1/VEGF bispecific antibody achieved response rates in a Phase 1/2 study that could rival the current leader in the space—findings that could help the pharma hold on to its cancer crown.

The findings, revealed Friday along with other abstracts at the American Association for Cancer Research’s annual meeting in San Diego, showed an unconfirmed overall response rate (ORR) of 55% in patients with non-small cell lung cancer who hadn’t undergone prior lines of treatment. The investigational therapy, dubbed MK-2010, hit 44% ORR when used as a second-line or later option.

“Data appears largely in line with Summit/Akeso’s ivonescimab,” analysts at BMO Capital Markets told investors in a Sunday afternoon note, referring to Merck’s chief competitor in this modality.

Summit Therapeutics and China’s Akeso are advancing the PD-1/VEGF bispecific ivonescimab, which is currently under FDA review for NSCLC with a decision expected in November. Some observers have dubbed ivonescimab as the Keytruda-killer after the partners in September 2024 showed that their bispecific antibody significantly outpaced Keytruda’s progression-free survival in a Phase 3 NSCLC study.

Most analysts have since tempered their optimism following a late-stage China study that resulted in an overall survival miss in May 2025 and signs of cross-country consistency problems in September that year.

Still, ivonescimab looms large over Merck’s new data. In a Monday note, BMO used ivonescimab’s Phase 3 ORR outcome of around 50% as a benchmark for MK-2010. “For MK-2010 to be meaningfully competitive in the PD-(L)1xVEGF treatment landscape, high ORRs that translate to survival outcomes in later-stage studies are needed,” the analysts said.

RBC Capital Markets agreed, noting on Friday that the Phase 1/2 findings support further development for MK-2010 and “puts Merck back in contention in the increasingly competitive PD-1×VEGF space.” Yet, the analysts wrote, the readout “lacks a distinctive edge.”

Merck “remains significantly behind” ivonescimab, the RBC analysts wrote, with Summit “substantially ahead.”

For Leerink Partners, Summit’s lead doesn’t seem so insurmountable. Merck has a “strong portfolio to leapfrog the competition via antibody-drug conjugate combinations,” analysts told investors in a Sunday note.

MK-2010 came to Merck in November 2024 when it partnered with Shanghai-based LaNova Medicines for $588 million upfront and up to $2.7 billion in milestones. In July 2025, Sino Biopharmaceutical bet up to $951 million to absorb LaNova.

https://www.biospace.com/drug-development/mercks-early-pd-1-vegf-data-competitive-in-lung-cancer-but-summit-looms-large

Odyssey tests IPO waters anew after quitting quest last year

 

Odyssey Therapeutics

Raise: TBD
Public Market Debut: TBD

Odyssey Therapeutics is giving its IPO aspirations another go, announcing on April 17 another bid to debut on the Nasdaq Capital Market. The biotech is still fairly early into its offering, so it has yet to provide a specific raise target or a definitive timeline for the push.

The company has, however, determined that its IPO proceeds will go toward its lead candidate OD-001, a small-molecule scaffolding blocker of the RIPK2 protein, according to its preliminary prospectus. The money will help move OD-001 through planned Phase 2a and Phase 2b studies in ulcerative colitis.

Odyssey’s IPO will also help push the SLC15A4 program OD-002 through investigational new drug-enabling activities and into Phase 1/2a development. “These programs have the potential to yield treatments for inflammatory and autoimmune diseases that have large, addressable patient populations globally,” the biotech wrote in its securities filing.

Odyssey first tried for an IPO in January 2025, though the biotech’s programs were still preclinical at the time. In June last year, Odyssey decided to end its bid. It did not provide specific reasons for pulling its IPO, only noting in an SEC document that going public “is not in the best interests of the company.”

https://www.biospace.com/business/ipo-tracker-2026

Agenus cancer cocktail records 0% response rate, missing midstage goal

 

An investigational cocktail was tied to a 0% overall response rate in patients with gastroesophageal cancer, but developers Agenus and MiNK Therapeutics aren’t giving up on the program just yet.

A cancer cocktail in development by Agenus and its spinout MiNK Therapeutics failed to elicit an overall response in a Phase 2 study, though the companies say other survival findings support continued efforts.

The biotechs were hoping the combination of Agenus’ two experimental immunotherapies botensilimab (BOT) and balstilimab (BAL), plus MiNK’s allogeneic cell therapy agenT-797, would improve overall response rate (ORR) for patients with gastroesophageal adenocarcinoma. The approved VEGFR2 antagonist Cyramza and chemotherapy were also added to the treatment regimen.

However, the investigational cocktail failed to elicit any complete or partial response among 15 eligible patients, according to an efficacy analysis set to be shared Monday afternoon at the American Association for Cancer Research (AACR) Annual Meeting. Patients included in the findings were diagnosed with advanced disease that has not responded to PD-1 treatment.

A previous Phase 3 trial showed that second-line treatment with Cyramza and chemotherapy was tied to an ORR of 28% and median progression free survival (PFS) of 4.4 months.

While the Agenus-MiNK candidate missed the trial’s primary goal, the biotechs pointed elsewhere to a 73% stable disease rate. Three patients also saw overall survival of more than 20 months, including one who has remained progression free after more than 22 months.

The companies also zeroed in on results from a subpopulation of patients receiving an induction cycle of the cocktail. Those patients had a PFS of 6.9 months compared to 3.5 months for the 10 patients who started all the therapies together.

The induction strategy was also tied to higher survival rates at 12 and 18 months, findings the companies say signal immune activation and tumor reprogramming.

Based on the subset data, Agenus and MiNK believe durability and survival “may be the most clinically relevant endpoints” in this specific patient population, according to the companies’ release shared on Friday. The subset findings “support further study of this approach,” they said.

As for safety, all patients experienced an adverse event (AE). Of 17 total patients, 53% experienced events of grade 3 or higher. The partners did not share further details on potential grade 4 and 5 events.

The safety data are “consistent with the component agents,” the companies said, adding that the most frequent treatment-emergent adverse events were fatigue, fever and diarrhea. Nine patients (53%) experienced an immune-related AE, with four of those events classified as grade 3 or higher events.

Agenus has been assessing its anti-CTLA-4 antibody BOT and PD-1 blocker BAL across several cancer types. The biotech recently launched a Phase 3 trial for the investigational combo in metastatic colorectal cancer and is prepping for potential future regulatory submissions in the U.S. and Europe.

In 2021, the Massachusetts-based biotech spun out its invariant natural killer T (iNKT) cell therapy agenT-797, creating MiNK. MiNK is testing agenT-797 in several indications, including a midstage study in severe acute lung injury. The New York spinout also touts a tech platform to develop other iNKT candidates and has several other programs in earlier-stage development.

https://www.biospace.com/drug-development/agenus-cancer-cocktail-records-0-response-rate-missing-midstage-goal

Israeli, Lebanese envoys said to meet on Thursday

 Israeli Ambassador to the United States Yechiel Leiter (pictured left) and his Lebanese counterpart Nada Hamadeh Moawad (pictured right) are set to meet in Washington on Thursday for a second round of direct negotiations, The Times of Israel reported on Monday, citing an Israeli official.

According to the report, the meeting between the Israeli and Lebanese officials, along with the American delegation, will take place at the US State Department, after the two ambassadors previously held a two-hour meeting last Tuesday, mediated by US Secretary of State Marco Rubio.

The meeting of the two delegations comes amid preparations for Israeli Prime Minister Benjamin Netanyahu and Lebanese President Joseph Aoun's visit to the US, which is set to take place after Israel's Independence Day on Wednesday.

https://breakingthenews.net/Article/Israeli-Lebanese-envoys-said-to-meet-on-Thursday/66105730

Trump open to direct talks with Iran leaders

 United States President Donald Trump told The New York Post in an interview published on Monday that he would "have no problem meeting" the Iranian leadership if a breakthrough is achieved in the negotiations between the two countries.

"If they want to meet, and we have some very capable people — but I have no problem meeting them," Trump said, while also confirming that the US delegation, led by Vice President JD Vance, is on its way to Pakistan for another round of talks with Iran. "They're heading over now," he confirmed. "They’ll be there tonight [Pakistan time]."

Furthermore, Trump stated that "we have pretty good ideas" about who is in charge of Iran now, adding that "we think we're dealing with the right people." Moreover, he reiterated that, for the negotiations to succeed, Iran must "get rid of their nuclear weapons," or "it wouldn't be pretty."

https://breakingthenews.net/Article/Trump-open-to-direct-talks-with-Iran-leaders/66105788